COMMUNIQUÉS West-GlobeNewswire

-
BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented
26/09/2025 -
Dogecoin Cash, Inc. (OTCQB: DOGP) Subsidiary PrestoDoctor Expands Telehealth Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide
26/09/2025 -
RadNet, Inc. to Present at the Jefferies Healthcare Services Conference on September 29, 2025
26/09/2025 -
ADvantage Therapeutics Awarded $2.5 milion NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
26/09/2025 -
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
26/09/2025 -
Harrow to Acquire Melt Pharmaceuticals
26/09/2025 -
Sanuwave Announces Strategic Debt Refinancing with New Credit Facility
26/09/2025 -
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
26/09/2025 -
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
26/09/2025 -
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
26/09/2025 -
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
26/09/2025 -
Ipsen et BioLabs Hôtel-Dieu décernent le Golden Ticket Ipsen 2025 à DETERA Therapeutics
26/09/2025 -
Fangzhou’s ‘XingShi’ LLM Featured by Nature News and Xinhua, Showcasing AI Innovation in Chronic Disease Care
26/09/2025 -
Concept Life Sciences Expands Integrated Drug Discovery Facilities
26/09/2025 -
uniQure Announces Pricing of Upsized $300 Million Public Offering
26/09/2025 -
OSE Immunotherapeutics, Inserm Transfert et Nantes Université annoncent un partenariat stratégique pour accélérer l’innovation en immunothérapie
26/09/2025 -
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
26/09/2025 -
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
26/09/2025 -
Grant of Restricted Stock Units and Warrants to Employees in Genmab
26/09/2025
Pages